King, Declan

Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer’s Disease

Pickett, E. K., Herrmann, A. G., McQueen, J., Abt, K., Dando, O., Tulloch, J., Jain, P., Dunnett, S., Sohrabi, S., Fjeldstad, M. P., et al. (2019) · Cell Reports

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 179

Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease

Colom-Cadena, M., Toombs, J., Simzer, E., Holt, K., McGeachan, R., Tulloch, J., Jackson, R. J., Catterson, J. H., Spires-Jones, M. P., Rose, J., et al. (2024) · Acta Neuropathologica

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 44

Evaluation of [ 3 H]SynVesT‐1 binding parameters in post‐mortem brain tissue from control and Alzheimer's Disease

Lemoine, L., Kulagowska, L., Bonsall, D., King, D., Gladstein, S., Bevis, A., Sabandal, M., Wells, L., Finnema, S. J., Spires‐Jones, T. L., et al. (2025) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 1

Using high‐resolution array tomography to validate the use of synaptic vesicle glycoprotein 2A as a biomarker for synaptic loss in Alzheimer's disease

Young, L., King, D., Chang, Y. Y., Holt, K., Gladstein, S., Finnema, S. J., & Spires‐Jones, T. L. (2025) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 1